ClinicalTrials.gg
Not yet recruitingNCT07230366Updated Dec 10, 2025

Clinical Validation of AI-powered Smart Vehicle Assisted Gait Training in Neurodegenerative Disorders

An interventional study of BestShape Go Intelligent Generation Transformable Electric Vehicle in Parkinson's Disease (PD) and Dementia, sponsored by Taipei Medical University Shuang Ho Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.

Planned enrollment
12th of 99
120 · median 55
Started
2026
with 6 others
No phase
72 of 121
23 open now
Primary completion
2028-12
later than 29 of 36 live
Registered
111th of 121
by date
Lead sponsor
5 of 121
Taipei Medical University Shuang Ho Hospital

Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 12th largest by planned enrollment of the 99 interventional ones that give a count, is one of 7 that started in 2026, is one of 72 with no phase, reaches primary completion later than 29 of the 36 other live ones, and was the 111th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Parkinson Disease with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to verify the safety and preliminary clinical benefits of long-term gait training using AI-powered smart electric vehicles for patients with neurodegenerative diseases such as Parkinson's disease and dementia.

Read the detailed description

This study is a single-center, prospective, open-label clinical intervention trial aimed at verifying the clinical safety and preliminary efficacy of an AI-powered smart electric vehicle in gait training for patients with Parkinson's disease and dementia. It is expected to recruit 120 participants aged 50-85 years, who will be randomly assigned to different training durations (2\~12 weeks), with training sessions conducted two or three times a week, each lasting 30 to 60 minutes. The primary assessment indicators include gait speed, number of falls, and gait confidence scale, while secondary assessments include satisfaction and balance function. All study data will be coded and preserved for 10 years. The study is funded by the "Healthy Taiwan Cultivation Plan."

03

Conditions studied

  • Parkinson's Disease (PD)
  • Dementia

Keywords

  • Neurodegenerative Diseases, Smart Electric Vehicles, Gait Training
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with neurodegenerative diseases (such as Parkinson's disease or dementia).
  2. Age between 50-85 years.
  3. Capable of walking for at least 10 meters, but may have unsteady gait or history of falls.
  4. Able to understand the trial procedures and give .

Exclusion criteria

Exclusion Criteria:

  1. Severe cardiopulmonary disease or recent major surgery.
  2. Unable to walk or requiring comprehensive physical support.
  3. Severe cognitive impairment preventing understanding of the trial procedures or giving .
  4. Visual or auditory impairments severe enough to prevent following trial instructions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    Gait abnormalities in patients with neurodegenerative diseases

    Device: BestShape Go Intelligent Generation Transformable Electric Vehicle

Interventions

  • DeviceBestShape Go Intelligent Generation Transformable Electric Vehicle

    The specific applications of artificial intelligence in intelligent electric vehicles mainly include gait monitoring and analysis, real-time feedback and guidance, autonomous adaptive assistance, safety prevention and warnings, data collection and longterm tracking, as well as adding interactive and entertainment elements.

06

What researchers measure

Primary outcomes

  1. Gait speed

    Time frame: Before & after training (the training sessions will last for 2~12 weeks).

Secondary outcomes

  1. Gait length

    Time frame: Before & after training (the training sessions will last for 2~12 weeks).

  2. Number of falls

    Time frame: During 2~12 training sessions.

  3. Patients' gait confidence scale

    Time frame: Before & after training (the training sessions will last for 2~12 weeks).

  4. Patients' balance function

    Timed-up-and-Go Test

    Time frame: Before & after training (the training sessions will last for 2~12 weeks).

  5. Patients' feedback

    Clinical Global Impression (CGI)

    Time frame: Before & after training (the training sessions will last for 2~12 weeks).

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2028, 35 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 35 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Nov 17, 2025
StartEst.
Jan 2, 2026
Primary completionEst.
Dec 10, 2028
CompletionEst.
Dec 31, 2028
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07230366
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Jan 2, 2026 (estimated)
Primary completion
Dec 10, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 10, 2025

Study contacts

Chien Tai Hong, MD, PhD
Contact
15004@s.tmu.edu.tw
+886 970747668
Likai Huang, MD
Contact
greatoriole@gmail.com
Lung Chan, MD, PhD
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion